The rate of mother-to-child transmission (MTCT) of HIV from breastfeeding is increasing relative to other causes of MTCT. Early effective preconception and antenatal antiretroviral therapy (ART) reduces intrauterine and intrapartum MTCT, whereas maternal post-partum HIV acquisition, untreated maternal HIV, and suboptimal postnatal maternal ART adherence increase the risk of MTCT through breastfeeding. Although the absolute number of cases of MTCT acquired through breastfeeding is decreasing, the rate of decrease is less than the decrease in intrauterine and intrapartum MTCT. Unless current strategies are universally applied, they might not be sufficient to eliminate MTCT due to breastfeeding. Urgent action is needed to evaluate and implement additional preventive biomedical strategies in high HIV prevalence and incidence settings to eliminate MTCT from breastfeeding. Preventive strategies include: pre-exposure prophylaxis in breastfeeding women who have an increased risk of acquiring HIV; postnatal reinforcement strategies, such as maternal retesting for HIV, maternal care reinforcement, and prophylaxis in infants exposed to HIV via breastmilk; and active (vaccine) or passive immunoprophylaxis with long-acting broadly neutralising antibodies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(21)00570-5DOI Listing

Publication Analysis

Top Keywords

mtct breastfeeding
12
hiv
8
mtct
8
intrauterine intrapartum
8
intrapartum mtct
8
eliminate mtct
8
breastfeeding
6
maternal
5
eliminating postnatal
4
postnatal hiv
4

Similar Publications

Article Synopsis
  • Ethiopia is working towards eliminating mother-to-child transmission (MTCT) of HIV by 2030, with a focus on optimizing Dolutegravir-based antiretroviral treatment (ART) since 2020.
  • A study analyzed HIV-exposed infants enrolled in Prevention of Mother-to-Child Transmission (PMTCT) care from 2017 to 2022, indicating low rates of HIV positivity at various intervals: 1.2% at 6-8 weeks, 0.50% during breastfeeding, and 1.8% by the end of care.
  • Results suggested a decreasing trend in transmission rates after the introduction of the DTG-based regimen; however, statistical significance was not achieved, and
View Article and Find Full Text PDF

Barriers and facilitators of a large clinical trial on prevention of HIV transmission through breastfeeding in Lusaka, Zambia: a qualitative study.

BMC Public Health

December 2024

Pathogenesis and Control of Chronic and Emerging Infections, Univ Montpellier, INSERM, EFS, Univ Antilles, Montpellier, France.

Article Synopsis
  • The PROMISE-EPI trial tested a combination of strategies to reduce HIV transmission during breastfeeding, showing better results than standard care, particularly through early diagnosis of infants and monitoring of maternal viral load.
  • In Zambia, the standard care differs with more complex preventative measures, leading to an exploration of facilitators and barriers related to the new intervention to inform future implementation.
  • Qualitative interviews and focus groups highlighted the benefits of integrating key intervention components for immediate action, trust in healthcare, and potential setbacks during disruptions like the COVID-19 pandemic.
View Article and Find Full Text PDF

Introduction: Mother-to-child transmission (MTCT) of HIV accounts for over 90% of annual HIV infections among children under the age of 15. Despite the introduction of the Option B+ strategy in Ethiopia in 2013, the rate of MTCT of HIV at 18 months was 15% in 2020. This study aimed to identify determinants of HIV infection among HIV-exposed infants (HEIs) in the context of prevention of MTCT (PMTCT) care in southern Ethiopia.

View Article and Find Full Text PDF

Introduction: Viral suppression is a critical component for preventing mother-to-child transmission of HIV(MTCT). Mothers' perceptions of viral load suppression is crucial in the attainment of successful outcomes in preventing mother to child transmission of HIV. We therefore aimed to explore the experiences and perceptions of women on viral suppression.

View Article and Find Full Text PDF

Objectives: To assess the efficacy and safety of a two-drug regimen (2DR) with dolutegravir (DTG) and lamivudine (3TC) in maintaining viral suppression during pregnancy and breastfeeding, and to evaluate its potential as an alternative to the recommended three-drug regimen (3DR) in preventing mother-to-child transmission (MTCT) of HIV.

Methods: We present a case of a 34-year-old pregnant woman who, after discontinuing 3DR due to side effects and poor adherence, was switched to DTG/3TC at gestational week 23. Maternal viral load (VL) and infant HIV status were monitored throughout pregnancy and a ten-month breastfeeding period.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!